Drug Resistance, Neoplasm
"Drug Resistance, Neoplasm" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Resistance or diminished response of a neoplasm to an antineoplastic agent in humans, animals, or cell or tissue cultures.
| Descriptor ID |
D019008
|
| MeSH Number(s) |
G07.690.773.984.395
|
| Concept/Terms |
Drug Resistance, Neoplasm- Drug Resistance, Neoplasm
- Resistance, Antineoplastic Agent
- Resistance, Antineoplastic Drug
- Drug Resistance, Antineoplastic
- Neoplasm Drug Resistance
- Antineoplastic Agent Resistance
- Antineoplastic Drug Resistance
|
Below are MeSH descriptors whose meaning is more general than "Drug Resistance, Neoplasm".
Below are MeSH descriptors whose meaning is more specific than "Drug Resistance, Neoplasm".
This graph shows the total number of publications written about "Drug Resistance, Neoplasm" by people in this website by year, and whether "Drug Resistance, Neoplasm" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 2 | 3 |
| 1999 | 1 | 1 | 2 |
| 2000 | 1 | 1 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 2 | 3 |
| 2003 | 3 | 8 | 11 |
| 2004 | 4 | 2 | 6 |
| 2005 | 6 | 12 | 18 |
| 2006 | 3 | 7 | 10 |
| 2007 | 6 | 5 | 11 |
| 2008 | 5 | 6 | 11 |
| 2009 | 5 | 7 | 12 |
| 2010 | 5 | 10 | 15 |
| 2011 | 8 | 13 | 21 |
| 2012 | 6 | 5 | 11 |
| 2013 | 7 | 9 | 16 |
| 2014 | 16 | 14 | 30 |
| 2015 | 23 | 20 | 43 |
| 2016 | 13 | 18 | 31 |
| 2017 | 15 | 9 | 24 |
| 2018 | 17 | 18 | 35 |
| 2019 | 15 | 24 | 39 |
| 2020 | 18 | 19 | 37 |
| 2021 | 11 | 12 | 23 |
| 2022 | 0 | 10 | 10 |
| 2023 | 1 | 5 | 6 |
| 2024 | 8 | 11 | 19 |
| 2025 | 25 | 10 | 35 |
| 2026 | 15 | 5 | 20 |
To return to the timeline,
click here.
Below are the most recent publications written about "Drug Resistance, Neoplasm" by people in Profiles.
-
Overcoming menin inhibitor resistance in AML cells with combinations including BET proteins and a dual BRG1/BRM inhibitor. Blood. 2026 Jun 04; 147(23):2809-2820.
-
Loss of tumor suppressor NF2 mediates resistance to CAR T cell and anti-PD-1 therapy: Strategies to restore immunotherapy sensitivity. Med. 2026 Jul 10; 7(7):101149.
-
Targeted suppression of SPP1 inhibits tumor invasion and metastasis in NRF2 hyperactivated cisplatin resistant HNSCC. J Transl Med. 2026 May 22; 24(1).
-
Evolution of tumor subclones and T-cell dynamics underlie variable ibrutinib responses in Waldenstr?m macroglobulinemia. Blood. 2026 May 14; 147(20):2298-2314.
-
Dissecting Pirtobrutinib Resistance in Mantle Cell Lymphoma Through Single-Cell Multi-Omics. Am J Hematol. 2026 Jul; 101(7):1632-1649.
-
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer. Clin Cancer Res. 2026 Apr 15; 32(8):1454-1461.
-
Co-occurrence of transcriptionally distinct persister cell states underpins neoadjuvant therapy resistance in triple-negative breast cancer. Genome Med. 2026 04 09; 18(1).
-
Regulation of mitochondrial ROS by C15ORF48 in a basal cell subpopulation contributes to chemotherapy resistance in TNBC. Sci Adv. 2026 Apr 03; 12(14):eaec8684.
-
Loss of luminal lineage drives resistance to next-generation ERa antagonists in pretreated ER+ HER2- locally-advanced or metastatic breast cancer. Nat Commun. 2026 Apr 01; 17(1).
-
Myeloproliferative neoplasms with concomitant chronic myeloid leukemia are associated with TKI resistance and poor outcomes. Leukemia. 2026 May; 40(5):946-954.